PERSONAL GENOME DIAGNOSTICS INC.

In News

New Collaboration Moves the Needle on Precision Medicine - Cleveland Clinic

Cleveland Clinic - Jan 17, 2022

Liquid biopsy market flooded with opportunity - BioWorld MedTech

BioWorld MedTech - Mar 14, 2025

Personal Genome Diagnostics Raises $75 Million to Bring Regulated IVD Genomic Tests to Cancer Patients Worldwide - PR Newswire

PR Newswire - Jan 04, 2018

Labcorp to Acquire Personal Genome Diagnostics for $575M - Nasdaq

Nasdaq - Dec 23, 2021

Labcorp wins FDA OK for pan-solid tumor liquid biopsy - MedTech Dive

MedTech Dive - Aug 06, 2024

Personal Genome Diagnostics Launches PlasmaSELECT 64 Panel For Non-Invasive Pan-Cancer Tumor Profiling - BioSpace

BioSpace - Oct 04, 2016

Automated next-generation profiling of genomic alterations in human cancers - Nature

Nature - May 20, 2022

Labcorp Acquires Precision Oncology Testing Company PGDx for $450M - Inside Precision Medicine

Inside Precision Medicine - Dec 27, 2021

Elio Tissue Complete Assay Approved by FDA for Use in a Pembrolizumab-Based Trial - Targeted Oncology

Targeted Oncology - Dec 05, 2019

Personal Genome Diagnostics Appoints Megan Bailey CEO - I95 Business

I95 Business - Apr 24, 2020

Personal Genome Diagnostics nabs $103M in series C financing - BioWorld MedTech

BioWorld MedTech - Feb 10, 2021

Genome-wide repeat landscapes in cancer and cell-free DNA - Science | AAAS

Science | AAAS - Mar 13, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment